Lightlake Therapeutics Inc. Announces Arvind Agrawal Appointed Executive Vice President, Medical Affairs

NEW YORK, Feb. 9, 2015 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Arvind Agrawal has joined Lightlake as Executive Vice President, Medical Affairs, effective January 2015.

Mr. Agrawal brings over 20 years of experience in medical and public affairs, scientific communications, and clinical development to Lightlake. During his career, Mr. Agrawal has overseen, managed, and delivered global phase I-IV clinical studies and has extensive experience in the therapeutic areas of addiction, psychiatry, CNS, respiratory, cardiovascular, and diabetes.   

Prior to joining Lightlake, Mr. Agrawal was Head of Medical Affairs New Products at Mundipharma International, where he made significant advances in the development of a novel treatment for opioid addiction. 

As European Clinical and Scientific Affairs Director of Reckitt Benckiser Pharmaceuticals, he developed successful strategies leading to highly positive clinical, public, and legislative changes for the cost-effective treatment of opioid dependence.

Mr. Agrawal served three years at AstraZeneca plc as European Medical Affairs Manager prior to joining Reckitt Benckiser Pharmaceuticals. Managing a large team of medical managers from across Europe, he was responsible for the lifecycle management of late-stage development and marketed products and communicated new clinical data to a large community of stakeholders. 

Prior to his appointment at AstraZeneca plc as European Medical Affairs Manager, Mr. Agrawal served as a Therapy Area Specialist and Clinical Study Manager at AstraZeneca plc and a Medical Affairs Manager for GlaxoSmithKline plc, SmithKline Beecham plc, and Wellcome Pharmaceuticals, where he helped to launch pharmaceutical blockbusters Crestor (rosuvastatin) and Avandia (rosiglitazone).

Arvind Agrawal holds a MSc in Human & Applied Physiology from King's College, University of London, and serves as the Managing Director of Ekagra Ltd., a pharmaceutical medical affairs consultancy based in the United Kingdom.

"We are delighted to announce Arvind Agrawal has joined the Company as EVP, Medical Affairs," stated Dr. Roger Crystal, CEO of Lightlake. He added, "Arvind brings an extensive and impressive background in medical and clinical affairs, having worked with key global regulatory authorities. He joins us at an ideal time to lead our medical and clinical affairs as we advance our clinical trials and move our product pipeline forward now that we have partnered with Adapt Pharma Limited on our opioid overdose reversal product."

In December 2014, Lightlake announced a licensing deal with a subsidiary of Adapt Pharma Limited. In exchange for licensing its opioid overdose reversal treatment, Lightlake could receive potential development and sales milestone payments of more than $55 million, plus up to double-digit royalties.

About Lightlake Therapeutics Inc.

Lightlake Therapeutics Inc., a biopharmaceutical company, is using its expertise in opioid antagonists to build a platform of innovative intranasal naloxone solutions to common addictions and related disorders. Lightlake is developing a treatment to reverse opioid overdoses, which have reached epidemic proportions in the United States. Lightlake has collaborated on clinical trials with the National Institute on Drug Abuse, part of the National Institutes of Health, and has entered into a licensing deal with a subsidiary of Adapt Pharma Limited. Lightlake also has completed a Phase II clinical trial to treat Binge Eating Disorder. For more information please visit: http://www.lightlaketherapeutics.com (http://www.lightlaketherapeutics.com/).

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

News Release
Corporate Contact:
Lightlake Therapeutics Inc.
445 Park Avenue, 9^th Floor
New York, NY 10022
Dr. Roger Crystal, CEO
212-829-5546
[email protected]

Investor Relations Contact:
Amato and Partners, LLC
[email protected]

SOURCE Lightlake Therapeutics Inc.

Related Links

www.lightlaketherapeutics.com